AnPac Bio-Medical Science (ANPC) Announces December 16th IPO

AnPac Bio-Medical Science (ANPC) expects to raise $18 million in an initial public offering (IPO) on the week of December 16th, IPO Scoop reports. The company will be issuing 1,400,000 shares at $12.00-$14.00 per share.

In the last twelve months, AnPac Bio-Medical Science generated $1.6 million in revenue and had a net loss of $980,000. The company has a market cap of $228.7 million.

WestPark Capital and Univest Securities acted as the underwriters for the IPO.

AnPac Bio-Medical Science provided the following description of their company for its IPO: ”  We are a biotechnology company focusing on early cancer screening and detection. We market and sell a multi-cancer screening and detection test that uses our innovative, patented CDA technology and our proprietary CDA device. In addition to early cancer screening and detection, our CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence. “.

AnPac Bio-Medical Science was founded in 2010 and has 101 employees. The company is located at 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006, People’s Republic of China and can be reached via phone at +86-578-2051-6666.

Receive News & Ratings for AnPac Bio-Medical Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnPac Bio-Medical Science and related companies with MarketBeat.com's FREE daily email newsletter.